Prostvac + ipilimumab shows promise in management of mCRPC

Results from a small trial of Barvarian Nordic’s investigational drug Prostvac — used in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy) — appear to have shown relatively dramatic effects in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

A rising incidence of intermediate- and higher-risk prostate cancer … but what does this mean?

According to another paper to be presented at the Genitourinary Cancers Symposium in Orlando, Florida, that started this morning, there was a 6 percent increase in the proportion of patients being diagnosed with intermediate- or higher-risk prostate cancers between 2011 and 2013. … READ MORE …

Active surveillance is absolutely NOT appropriate for all men with intermediate-risk prostate cancer

A paper to be presented this Thursday at the upcoming Genitourinary Cancers Symposium in  Orlando, Florida, will clearly confirm the above heading, which should come as no surprise to anyone. The issue has always been whether there is a subset of men with (“favorable”) intermediate-risk disease who are potentially appropriate candidates. … READ MORE …

Half of long-term erectile function (EF) loss after brachytherapy (BT) is due to aging

One of the most important things we patients want to know about any treatment is what kind of potency we can expect afterwards. Urinary and rectal dysfunctions are often measured and reported by investigators, but sexual dysfunction is rarely reported or measured. … READ MORE …

In 2004-07 most Medicare-eligible men were getting radiation therapy for first-line treatment of prostate cancer

In a second article in the new journal JAMA Oncology, researchers at the University of California Los Angeles suggest that 58 percent of all relatively recent treatment for prostate cancer was being given by radiation therapy of some type, and that indolent prostate cancer was being significantly over-treated. … READ MORE …

Is active surveillance appropriate for men with favorable intermediate-risk prostate cancer?

In a paper in the first issue of the new journal JAMA Oncology, a group of US-based researchers argue that data from a series of > 5,000 patients treated with first-line brachytherapy suggest that men with favorable intermediate-risk prostate cancer are actually good candidates for active surveillance. … READ MORE …

IADT, dutasteride, and the AVIAS trial — not the result some would want to hear

So the initial results of the AVIAS trial are not going to make a couple of our regular readers too happy — although at least a trial of the type they have been asking for has now been carried out. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,245 other followers